SB-269970 |
Catalog No.GC37599 |
Le SB-269970 est un antagoniste des récepteurs 5-HT7 puissant, sélectif et pénétrant dans le cerveau avec un pKi de 8,3.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 201038-74-6
Sample solution is provided at 25 µL, 10mM.
SB269970 is a 5-HT7 receptor antagonist with pKi of 8.3, exhibits >50-fold selectivity against other receptors. pKi: 8.3 (5-HT7 receptor)[1]
SB-269970 (3-30 mg/kg; i.p.; once) significantly blocks amphetamine and ketamine-induced hyperactivity[2]. Animal Model: male C57BL6/J mice[2]
[1]. Hagan JJ, et al. Characterization of SB-269970-A, a selective 5-HT(7) receptor antagonist. Br J Pharmacol. 2000 Jun;130(3):539-48. [2]. Roberts C, et al. The effect of SB-269970, a 5-HT(7) receptor antagonist, on 5-HT release from serotonergic terminals and cell bodies. Br J Pharmacol. 2001 Apr;132(7):1574-80. [3]. Nikiforuk A, et al. Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS One. 2013 Jun 11;8(6):e66695. [4]. Monti JM, et al. The serotonin 5-HT7 receptor agonist LP-44 microinjected into the dorsal raphe nucleus suppresses REM sleep in the rat. Behav Brain Res. 2008 Aug 22;191(2):184-9.
Average Rating: 5
(Based on Reviews and 2 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *